[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"maturity-onset-diabetes-of-the-young\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:maturity-onset-diabetes-of-the-young":80},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100630771","china-monogenic-diabetes-registry-100630771",false,"NCT07492004","China Monogenic Diabetes Registry","CMDR","Inclusion Criteria:\n\n1. Diabetes diagnosed before 25 years of age; OR diabetes diagnosed before 35 years of age with ≥1 first-degree relative (parent, sibling, or offspring) diagnosed with diabetes before 40 years of age\n2. Body mass index (BMI) at diagnosis 28 kg\u002Fm²\n3. Negative glutamic acid decarboxylase antibody (GAD-Ab)\n\nExclusion Criteria:\n\n1. Secondary diabetes\n2. Active malignancy or history of malignant tumor within the past 5 years","ALL",{"count":18,"type":19},5000,"ESTIMATED","5 Years","OBSERVATIONAL","This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to:\n\nCharacterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution\n\nParticipants will:\n\n* Enroll in the monogenic diabetes registry via mobile application or web-based platform\n* Undergo molecular genetic testing to establish a definitive diagnosis",[24,25,26],"Neonatal Diabetes","Monogenic Diabetes","Maturity Onset Diabetes of the Young",[25,24,26],"RECRUITING","2026-03-19",{"date":31,"type":32},"2026-03-25","ACTUAL",{"date":34,"type":32},"2021-02-28",{"date":36,"type":19},"2030-07-31",{"name":38,"class":39},"Tianjin Medical University General Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100595173","phase-2-liraglutide-treatment-in-patients-with-maturity-onset-diabetes-of-the-young-mody-100595173","NCT07029009","Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)","Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)","Inclusion Criteria:\n\n* Diagnosis of MODY via genetic testing\n* HgbA1c \\>6.5%\n\nExclusion Criteria:\n\n* History of anaphylaxis to GLP-1 receptor agonists\n* Already taking GLP-1 receptor agonists\n* on medications within the stimulant class\n* have had bariatric surgery\n* personal or family history of cancer, especially medullary thyroid cancer\n* personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis\n* known active kidney disease\n* severe hypoglycemia (glucose \\\u003C 50 mg\u002FdL) within 3 months of study enrollment\n* HbA1c \\> 10.0%\n* episode of diabetic ketoacidosis (DKA) in the past 3 months\n* are currently pregnant\n* BMI \\\u003C 18.5 kg\u002Fm2 and pediatric patients with BMI \\\u003C 5th percentile","10 Years",{"count":50,"type":19},50,"INTERVENTIONAL",[53],"PHASE2","The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY).\n\nThe investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues.\n\nIf liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.",[26],"2025-12-12",{"date":58,"type":32},"2025-12-17",{"date":60,"type":32},"2025-05-08",{"date":62,"type":19},"2027-01",{"name":64,"class":39},"Mansa",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":51,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100484327","identifying-maturity-onset-diabetes-of-the-young-in-emirati-patients-100484327","NCT05586594","Identifying Maturity-onset Diabetes of the Young in Emirati Patients","Identifying Maturity-onset Diabetes of the Young in Susceptible Emirati Patients Who Are Currently Treated as Type 1 or Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Age \\> 11; both male or female, Emirati patients only\n* Diagnosed to have Type 1 or Type 2 Diabetes Mellitus diagnosed before the age of 40 and after the age of 6 months.\n* Attended Tawam hospital during the last 1 year.\n* All previous antibodies testing being negative.\n* Absence of ketoacidosis \u002F significant ketosis in the past medical records\n\nExclusion Criteria:\n\n* BMI of 40 or above (class 3 \u002F severe obesity)\n* History of Secondary diabetes (e.g. Diabetes following pancreatitis)\n* Absent\u002FDecreased C-peptide activity suggestive of Type 1 Diabetes","12 Years","45 Years",{"count":75,"type":19},150,[77],"NA","Diabetes Mellitus is a disease that affects nearly 1 in 5 people in United Arab Emirates and is one of leading causes of death and disability. The main reason for this condition is either relative or near complete deficiency of essential hormone made by our pancreas called \"insulin\", which is required to utilize blood sugar (glucose), and insulin shortage leads to increased blood glucose. The common types of this condition include type 2 Diabetes Mellitus (the most common with almost 90% of all diabetes patients having this condition), which is related to mismatch of body requirements and production of essential hormone called insulin (relative deficiency) and type 1 diabetes, in which body's own defense system causes of destruction of insulin producing cells in the pancreas (near complete deficiency of insulin). However, in younger age group (below the age of 35) there is another type of diabetes which affects nearly 1 out 1000 people and is Maturity onset diabetes of the young (MODY). MODY is a condition passed by parents in 50% of the kids due to an affected single gene and most common forms of MODY do not require any Insulin treatment. However as type 1 Diabetes is generally identified in younger age group, 80% of patient who have MODY cannot be diagnosed and are labelled with other forms of diabetes instead, and may receive unnecessary insulin injections. Although, there has been a lot of research done in the west on prevalence of MODY in white\u002FCaucasian population, the studies in Middle East are minimal. Also, in the white\u002FCaucasian population, a reliable risk calculator has been developed that predicts the risk of having MODY, which if found to be high, is then confirmed by genetic testing for MODY. There is no study available on presence of MODY or on the reliability of the MODY risk calculator among young Emirati population. There is also no data on MODY being misdiagnosed as other forms of diabetes in Emirati population.\n\nThis study proposal aims to address this gap of knowledge and assess the reliability of MODY calculator in young Emirati patients with diabetes and to see if any MODY patient exist in Diabetes clinics of Tawam hospital Abu Dhabi, who may have been misdiagnosed as type 1 or type 2.",[80,25,81],"Maturity-onset Diabetes of the Young","MODY",[83,84,85,86],"Maturity-onset Diabetes of the Young (MODY)","Diabetes Mellitus","Diagnosis","Precision Medicine","NOT_YET_RECRUITING","2024-01-10",{"date":90,"type":32},"2024-01-11",{"date":92,"type":19},"2024-03",{"date":94,"type":19},"2026-06",{"name":96,"class":39},"United Arab Emirates University"]